Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinsons Disease and Movement Disorders
– ARV-102 was well tolerated in clinical trials for both healthy volunteers…
XingImaging in partnership with SynuSight was awarded a grant from The Michael J. Fox Foundation to support development of the -synuclein PET tracer 18F-FD4 for Parkinson’s disease
NEW HAVEN, Conn., Sept. 10, 2025 /PRNewswire/ -- XingImaging in partnership with…
Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical…
